RY 133.21 -0.0675% TD 78.64 0.4599% SHOP 95.75 0.136% CNR 174.55 -0.2172% ENB 46.51 1.3511% CP 115.18 -0.3375% BMO 125.12 -0.1197% TRI 207.83 -1.3153% CNQ 105.4 -0.8467% BN 52.885 -1.5544% ATD 75.13 -0.186% CSU 3670.4399 -1.1052% BNS 64.03 -0.2959% CM 64.91 0.1698% SU 52.315 0.2587% TRP 48.59 0.5796% NGT 53.03 -0.0942% WCN 226.63 -0.0838% MFC 31.51 0.2226% BCE 44.31 -0.2476%

biOasis Technologies Inc

Healthcare CA BTI

0.01CAD
-(-%)

Last update at 2024-04-17T13:30:00Z

Day Range

0.010.01
LowHigh

52 Week Range

0.010.05
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-02-28 2021-02-28 2020-02-29 2019-02-28 2018-02-28
Type yearly yearly yearly yearly yearly
Date 2022-02-28 2021-02-28 2020-02-29 2019-02-28 2018-02-28
Income before tax -2.96009M 0.70M -4.05642M -3.47341M -5.30794M
Minority interest - - - - -
Net income -2.96009M 0.70M -4.05642M -3.47341M -5.30794M
Selling general administrative 2.41M 2.57M 3.17M 4.31M 4.45M
Selling and marketing expenses - - - - -
Gross profit - - 0.61M 1.41M 0.12M
Reconciled depreciation 0.05M 0.06M 0.07M 0.07M 0.06M
Ebit -3.59678M 0.38M -4.60168M -4.85717M -5.27725M
Ebitda -3.54186M 0.33M -4.53092M -4.78518M -5.21837M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income -3.59678M 0.27M -4.60168M -4.85717M -5.27725M
Other operating expenses - - - - -
Interest expense 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Tax provision - - - - -
Interest income - - - 0.00178M 0.01M
Net interest income -0.65421M -0.03585M -0.04690M 0.00178M 0.01M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - 0.00000M
Total revenue 0.04M 4.08M 0.61M 1.42M 0.59M
Total operating expenses 3.63M 3.81M 5.21M 6.28M 5.87M
Cost of revenue - - 0.00000M 0.01M 0.47M
Total other income expense net 1.29M 0.46M 0.59M 1.38M -0.04204M
Discontinued operations - - - - -
Net income from continuing ops -2.96009M 0.70M -4.05642M -3.47341M -5.30794M
Net income applicable to common shares -2.96009M 0.70M -4.05642M -3.47341M -5.30794M
Preferred stock and other adjustments - - - - -
Breakdown 2022-02-28 2021-02-28 2020-02-29 2019-02-28 2018-02-28
Type yearly yearly yearly yearly yearly
Date 2022-02-28 2021-02-28 2020-02-29 2019-02-28 2018-02-28
Total assets 2.27M 3.28M 0.94M 1.74M 1.22M
Intangible assets 0.16M 0.21M 0.27M 0.33M 0.39M
Earning assets - - - - -
Other current assets - - - - -
Total liab 4.18M 2.87M 3.43M 2.29M 0.79M
Total stockholder equity -1.91736M 0.41M -2.48628M -0.54666M 0.43M
Deferred long term liab - - - - -
Other current liab - - - 0.26M -
Common stock 27.45M 27.26M 25.42M 24.20M 22.79M
Capital stock 27.45M 27.26M 25.42M 24.20M -
Retained earnings -40.65397M -37.69387M -38.39229M -34.33586M -30.86245M
Other liab 0.79M 0.91M 0.43M 1.03M -
Good will - - - - -
Other assets - - - - -
Cash 1.73M 2.74M 0.58M 1.36M 0.68M
Cash and equivalents - - - - -
Total current liabilities 2.99M 1.90M 2.48M 1.26M 0.79M
Current deferred revenue - - - - -
Net debt 0.17M - 0.43M - -
Short term debt - - - - -
Short long term debt 1.50M 0.06M 0.49M - -
Short long term debt total - - - - -
Other stockholder equity 0.18M 0.19M 0.02M 0.03M 0.03M
Property plant equipment 0.00022M 0.00464M 0.02M 0.03M 0.04M
Total current assets 2.11M 3.06M 0.65M 1.38M 0.79M
Long term investments - - - - -
Net tangible assets -2.07632M 0.19M -2.75533M -0.87448M 0.05M
Short term investments - - - - -
Net receivables 0.10M 0.03M 0.01M 0.00971M 0.03M
Long term debt 0.40M 0.06M 0.52M - -
Inventory - - - - -
Accounts payable 1.49M 1.84M 1.99M 1.00M 0.79M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - 0.36M 0.43M
Deferred long term asset charges - - - - -
Non current assets total 0.16M 0.22M 0.29M 0.36M 0.43M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2022-02-28 2021-02-28 2020-02-29 2019-02-28 2018-02-28
Type yearly yearly yearly yearly yearly
Date 2022-02-28 2021-02-28 2020-02-29 2019-02-28 2018-02-28
Investments 0.00000M 0.00697M 0.00000M 0.39M -0.10771M
Change to liabilities -0.51303M 0.01M 0.74M 0.48M 0.04M
Total cashflows from investing activities - 0.00697M 0.00697M 0.39M -0.10771M
Net borrowings 2.53M -0.57596M 1.29M 1.29M 1.29M
Total cash from financing activities 2.64M 0.31M 2.49M 3.53M 3.90M
Change to operating activities 0.18M -0.24280M -0.04933M 0.07M 0.04M
Net income -2.96009M 0.70M -4.05642M -3.47341M -5.30794M
Change in cash -1.00597M 2.16M -0.78367M 0.68M 0.12M
Begin period cash flow 2.74M 0.58M 1.36M 0.68M 0.55M
End period cash flow 1.73M 2.74M 0.58M 1.36M 0.68M
Total cash from operating activities -3.63551M 1.77M -3.29865M -3.22967M -3.67314M
Issuance of capital stock 0.20M 0.19M 1.21M 3.53M -
Depreciation 0.05M 0.06M 0.07M 0.07M 0.06M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -0.06704M -0.01691M -0.00366M 0.02M 0.02M
Sale purchase of stock - - - - 3.90M
Other cashflows from financing activities -0.09043M -0.09043M -0.09043M -0.09043M -
Change to netincome -0.98314M 1.15M -0.05884M -0.39663M 1.47M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00206M 0.04M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.40170M -0.24753M 0.69M 0.57M 0.10M
Stock based compensation 0.44M 0.28M 0.57M 0.98M -
Other non cash items 0.65M 0.11M 0.05M - -
Free cash flow -3.63551M 1.77M -3.29865M -3.23174M -3.78085M

Fundamentals

  • Previous Close 0.01
  • Market Cap0.40M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2.98069M
  • Revenue TTM0.27M
  • Revenue Per Share TTM0.004
  • Gross Profit TTM -1.18843M
  • Diluted EPS TTM-0.04

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BTI
biOasis Technologies Inc
- -% 0.01 - - 1.47 54.04 9.11 -0.7845
NGEN
NervGen Pharma Corp
0.02 1.01% 2.00 - - - 29.48 -6.9477
ARCH
Arch Biopartners Inc
0.01 0.42% 2.39 - - 37.82 - 53.05 -28.1027
MIR
MedMira Inc
-0.01 11.11% 0.08 - - 170.46 - 189.94 -48.7372
TTI
Thiogenesis Therapeutics Corp.
0.06 8.11% 0.80 - - - 11.86 -163.0787

Reports Covered

Stock Research & News

Profile

Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.

biOasis Technologies Inc

157 Church Street, New Haven, CT, United States, 06510

Key Executives

Name Title Year Born
Dr. Deborah Ann Rathjen B.Sc. (Hons.), FTSE, M.A.I.C.D., Ph.D., Q.C. Exec. Chairman, CEO & Pres 1958
Mr. Dave Jenkins Chief Financial Officer NA
Mr. Graeme Dick Director of Investor Relations NA
Mr. Kim Elton Director of Marketing NA
Mr. Doug Williams MBA Exec. VP & Chief Bus. Officer NA
Dr. Mei Mei Tian VP & Head of External Research NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).